Nosopharm

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

French collaboration aims to address antibiotic resistance

The project will involve the creation of chemical libraries of bioactive molecules for Nosopharm’s anti-infective screening campaigns against antibiotic resistance
Recruitment

Nosopharm bolsters supervisory board
Research & Development

Nosopharm joins European Gram-negative Antibacterial Engine (ENABLE) project to combat antibiotic resistance

The company aims to advance a promising antibacterial compound to clinical stage for the treatment of multidrug-resistant Gram-negative infections
Research & Development

Nosopharm secures funding of €870,000 to fight antibiotic resistance

Nosopharm has developed a new class of antibiotics and the funding will ensure their progression to preclinical development
Subscribe now